Related Experiment Video
Updated: Feb 27, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
Transcription Factor RUNX1 Regulates Platelet PCTP (Phosphatidylcholine Transfer Protein): Implications for
Guangfen Mao1, Natthapol Songdej1, Deepak Voora1
1From Sol Sherry Thrombosis Research Center (G.M., N.S., F.E.D.C.-C., L.E.G., A.K.R.), Hematology Section, Department of Medicine (N.S., A.K.R.), and Department of Anatomy and Cell Biology (L.E.G.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; and Duke Center for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC (D.V., R.A.M.).
Insights
RUNX1 directly regulates phosphatidylcholine transfer protein (PCTP) gene expression. Higher PCTP levels in patients with cardiovascular disease correlate with increased risk of death or myocardial infarction.
Area of Science:
- Hematology
- Molecular Biology
- Cardiovascular Research
Background:
- Phosphatidylcholine transfer protein (PCTP) regulates phosphatidylcholine transfer between membranes.
- Elevated PCTP in platelets is linked to increased responses in Black subjects.
- RUNX1, a hematopoietic transcription factor, loss-of-function mutations impair platelet function and reduce PCTP expression.
Purpose of the Study:
- To investigate if RUNX1 regulates PCTP expression.
- To determine if PCTP expression correlates with cardiovascular events.
Main Methods:
- DNA-protein binding and luciferase reporter assays to assess RUNX1 binding to the PCTP promoter.
- Analysis of peripheral blood RNA from two patient cohorts (587 total) to correlate RUNX1 and PCTP expression.
- Association studies between PCTP expression and cardiovascular outcomes (death/myocardial infarction).
Main Results:
- RUNX1 binds to the PCTP promoter, confirming direct transcriptional regulation.
- PCTP expression increases with RUNX1 overexpression and decreases with RUNX1 knockdown in cell lines.
- In patients, RUNX1 expression correlates with PCTP expression, which is higher in Black subjects.
- Elevated PCTP expression is associated with future death/myocardial infarction (OR 2.05).
Conclusions:
- PCTP is a direct transcriptional target of RUNX1.
- PCTP expression is a significant predictor of adverse cardiovascular outcomes.
- RUNX1-mediated regulation of PCTP may contribute to platelet-mediated cardiovascular events.
Background:
PCTP (phosphatidylcholine transfer protein) regulates the intermembrane transfer of phosphatidylcholine. Higher platelet PCTP expression is associated with increased platelet responses on activation of protease-activated receptor 4 thrombin receptors noted in black subjects compared with white subjects. Little is known about the regulation of platelet PCTP. Haplodeficiency of RUNX1, a major hematopoietic transcription factor, is associated with thrombocytopenia and impaired platelet responses on activation. Platelet expression profiling of a patient with a RUNX1 loss-of-function mutation revealed a 10-fold downregulation of the PCTP gene compared with healthy controls.
Methods:
We pursued the hypothesis that PCTP is regulated by RUNX1 and that PCTP expression is correlated with cardiovascular events. We studied RUNX1 binding to the PCTP promoter using DNA-protein binding studies and human erythroleukemia cells and promoter activity using luciferase reporter studies. We assessed the relationship between RUNX1 and PCTP in peripheral blood RNA and PCTP and death or myocardial infarction in 2 separate patient cohorts (587 total patients) with cardiovascular disease.
Results:
Platelet PCTP protein in the patient was reduced by ≈50%. DNA-protein binding studies showed RUNX1 binding to consensus sites in ≈1 kB of PCTP promoter. PCTP expression was increased with RUNX1 overexpression and reduced with RUNX1 knockdown in human erythroleukemia cells, indicating that PCTP is regulated by RUNX1. Studies in 2 cohorts of patients showed that RUNX1 expression in blood correlated with PCTP gene expression; PCTP expression was higher in black compared with white subjects and was associated with future death/myocardial infarction after adjustment for age, sex, and race (odds ratio, 2.05; 95% confidence interval 1.6-2.7; P<0.0001). RUNX1 expression is known to initiate at 2 alternative promoters, a distal P1 and a proximal P2 promoter. In patient cohorts, there were differential effects of RUNX1 isoforms on PCTP expression with a negative correlation in blood between RUNX1 expressed from the P1 promoter and PCTP expression.
Conclusions:
PCTP is a direct transcriptional target of RUNX1. PCTP expression is associated with death/myocardial infarction in patients with cardiovascular disease. RUNX1 regulation of PCTP may play a role in the pathogenesis of platelet-mediated cardiovascular events.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Regulation of Angiogenesis and Blood Supply
General Transcription Factors
Transcription Factors
Cell Specific Gene Expression
Pleiotropy

